Precigen, Inc. (NASDAQ:PGEN) Given Average Recommendation of "Moderate Buy" by Analysts

Key Points

• Analysts maintain a “Moderate Buy” consensus on Precigen, with three buy ratings, one strong-buy rating and one sell rating. The average 12-month price target is $14.50, compared with the stock’s reported $6.95 price.
• Precigen reported quarterly results above expectations, posting $0.05 earnings per share versus a $0.01 loss estimate and $54.98 million in revenue versus $27.98 million expected. Revenue increased more than 6,300% year over year.
• Insiders sold shares totaling about $6.2 million during the last quarter, while institutional ownership increased among several investors; insiders own 41.4% of the company and institutions hold 33.51%.

Shares of Precigen, Inc. (NASDAQ:PGEN - Get Free Report) have been given a consensus rating of "Moderate Buy" by the five ratings firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $14.50.

A number of equities analysts have weighed in on the stock. HC Wainwright raised their target price on shares of Precigen from $14.00 to $18.00 and gave the company a "buy" rating in a research note on Wednesday, August 5th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Precigen in a research note on Friday, July 17th. Zacks Research raised Precigen from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, August 5th. Wall Street Zen raised Precigen from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 8th. Finally, Citigroup reissued an "outperform" rating on shares of Precigen in a research report on Thursday, May 14th.

Insiders Place Their Bets

In other news, CFO Harry Jr. Thomasian sold 100,000 shares of the business's stock in a transaction on Friday, July 31st. The stock was sold at an average price of $6.06, for a total value of $606,000.00. Following the completion of the transaction, the chief financial officer owned 254,535 shares in the company, valued at $1,542,482.10. The trade was a 28.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Rutul R. Shah sold 15,342 shares of Precigen stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $7.50, for a total value of $115,065.00. Following the completion of the sale, the chief operating officer owned 468,865 shares of the company's stock, valued at $3,516,487.50. The trade was a 3.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 991,271 shares of company stock valued at $6,208,620. 41.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Precigen

A number of institutional investors and hedge funds have recently modified their holdings of the company. AQR Capital Management LLC increased its position in Precigen by 216.9% during the first quarter. AQR Capital Management LLC now owns 63,179 shares of the biotechnology company's stock valued at $94,000 after acquiring an additional 43,245 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Precigen by 12.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 81,610 shares of the biotechnology company's stock worth $122,000 after purchasing an additional 9,043 shares during the period. Strs Ohio purchased a new stake in Precigen during the first quarter valued at approximately $70,000. Geode Capital Management LLC boosted its stake in shares of Precigen by 7.7% during the 2nd quarter. Geode Capital Management LLC now owns 3,749,182 shares of the biotechnology company's stock worth $5,325,000 after acquiring an additional 269,580 shares during the last quarter. Finally, Creative Planning increased its stake in shares of Precigen by 127.8% in the 2nd quarter. Creative Planning now owns 94,291 shares of the biotechnology company's stock worth $134,000 after purchasing an additional 52,901 shares in the last quarter. 33.51% of the stock is currently owned by hedge funds and other institutional investors.

Precigen Stock Down 3.3%

PGEN stock opened at $6.95 on Friday. Precigen has a fifty-two week low of $2.99 and a fifty-two week high of $7.72. The company has a market capitalization of $2.48 billion, a price-to-earnings ratio of -6.68 and a beta of 1.02. The business's 50 day moving average price is $6.05 and its two-hundred day moving average price is $4.75. The company has a debt-to-equity ratio of 2.15, a quick ratio of 3.89 and a current ratio of 4.58.

Precigen (NASDAQ:PGEN - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported $0.05 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $0.06. Precigen had a positive return on equity of 423.75% and a negative net margin of 183.98%.The company had revenue of $54.98 million for the quarter, compared to analyst estimates of $27.98 million. The firm's quarterly revenue was up 6322.7% compared to the same quarter last year. As a group, analysts forecast that Precigen will post 0.25 earnings per share for the current fiscal year.

Precigen Company Profile

Precigen, Inc NASDAQ: PGEN is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen's approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen's technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source